Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 4,180 shares at $142.20 ($587K) on 2024-02-06, disclosed to the SEC on 2024-02-08.
Scheduled sale ($587k) by Chief Business Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $142.20 | 1,600 | $228K | 38.8% |
| 2 | $142.20 | 1,600 | $228K | 38.8% |
| 3 | $134.20 | 980 | $132K | 22.4% |
| Total | $140.32 avg | 4,180 | $587K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |